Literature DB >> 28648617

A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.

Nicholas C Wu1, Ian A Wilson2.   

Abstract

Influenza virus evolves rapidly to constantly escape from natural immunity. Most humoral immune responses to influenza virus target the hemagglutinin (HA) glycoprotein, which is the major antigen on the surface of the virus. The HA is composed of a globular head domain for receptor binding and a stem domain for membrane fusion. The major antigenic sites of HA are located in the globular head subdomain, which is highly tolerant of amino acid substitutions and continual addition of glycosylation sites. Nonetheless, the evolution of the receptor-binding site and the stem region on HA is severely constrained by their functional roles in engaging the host receptor and in mediating membrane fusion, respectively. Here, we review how broadly neutralizing antibodies (bnAbs) exploit these evolutionary constraints to protect against diverse influenza strains. We also discuss the emerging role of other epitopes that are conserved only in subsets of viruses. This rapidly increasing knowledge of the evolutionary biology, immunology, structural biology, and virology of influenza virus is invaluable for development and design of more universal influenza vaccines and novel therapeutics.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibody; evolution; hemagglutinin; influenza A virus; protein structure

Mesh:

Substances:

Year:  2017        PMID: 28648617      PMCID: PMC5573227          DOI: 10.1016/j.jmb.2017.06.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  191 in total

1.  Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells.

Authors:  Y Kawaoka; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

2.  Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site.

Authors:  M N Matrosovich; A S Gambaryan; S Teneberg; V E Piskarev; S S Yamnikova; D K Lvov; J S Robertson; K A Karlsson
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

3.  A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission.

Authors:  Terrence M Tumpey; Taronna R Maines; Neal Van Hoeven; Laurel Glaser; Alicia Solórzano; Claudia Pappas; Nancy J Cox; David E Swayne; Peter Palese; Jacqueline M Katz; Adolfo García-Sastre
Journal:  Science       Date:  2007-02-02       Impact factor: 47.728

4.  An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex.

Authors:  Lalitha Venkatramani; Elena Bochkareva; Janis T Lee; Upma Gulati; W Graeme Laver; Alexey Bochkarev; Gillian M Air
Journal:  J Mol Biol       Date:  2005-12-07       Impact factor: 5.469

5.  Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.

Authors:  Xiaoquan Wang; Natalia A Ilyushina; Vladimir Y Lugovtsev; Nicolai V Bovin; Laura K Couzens; Jin Gao; Raymond P Donnelly; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

6.  Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin.

Authors:  Joshua L Cherry; David J Lipman; Anastasia Nikolskaya; Yuri I Wolf
Journal:  PLoS Curr       Date:  2009-08-18

7.  Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Authors:  Aaron G Schmidt; Huafeng Xu; Amir R Khan; Timothy O'Donnell; Surender Khurana; Lisa R King; Jody Manischewitz; Hana Golding; Pirada Suphaphiphat; Andrea Carfi; Ethan C Settembre; Philip R Dormitzer; Thomas B Kepler; Ruijun Zhang; M Anthony Moody; Barton F Haynes; Hua-Xin Liao; David E Shaw; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-21       Impact factor: 11.205

Review 8.  Pathogenic responses among young adults during the 1918 influenza pandemic.

Authors:  G Dennis Shanks; John F Brundage
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

9.  A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

Authors:  Ying Wu; MyungSam Cho; David Shore; Manki Song; JungAh Choi; Tao Jiang; Yong-Qiang Deng; Melissa Bourgeois; Lynn Almli; Hua Yang; Li-Mei Chen; Yi Shi; Jianxu Qi; An Li; Kye Sook Yi; MinSeok Chang; Jin Soo Bae; HyunJoo Lee; JiYoung Shin; James Stevens; SeoungSuh Hong; Cheng-Feng Qin; George F Gao; Shin Jae Chang; Ruben O Donis
Journal:  Nat Commun       Date:  2015-07-21       Impact factor: 14.919

10.  Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses.

Authors:  Ben M Hause; Mariette Ducatez; Emily A Collin; Zhiguang Ran; Runxia Liu; Zizhang Sheng; Anibal Armien; Bryan Kaplan; Suvobrata Chakravarty; Adam D Hoppe; Richard J Webby; Randy R Simonson; Feng Li
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

View more
  74 in total

1.  Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses.

Authors:  Nicholas C Wu; Andrew J Thompson; Juhye M Lee; Wen Su; Britni M Arlian; Jia Xie; Richard A Lerner; Hui-Ling Yen; Jesse D Bloom; Ian A Wilson
Journal:  Science       Date:  2020-06-19       Impact factor: 47.728

2.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Post-pandemic influenza-associated mortality in Mexico.

Authors:  Jack N Salto-Quintana; Gerardo Rivera-Alfaro; Evelyn L Sánchez-Ramos; Alejandro Gómez-Gómez; Daniel E Noyola
Journal:  Pathog Glob Health       Date:  2019-03-21       Impact factor: 2.894

Review 4.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

Review 5.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 6.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

7.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

Review 8.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

9.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

Review 10.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.